natgillin/translations-raw huggingface dataset:
compacting the lubricated blend to ribbons of density in a range of 1.1 to 1.2 g/mL and sizing the compacted ribbons using a roller compactor, 
zbijanje ovlažene smjese u trake gustoće u opsegu od 1.1 do 1.2 g/mL i formiranje do dane veličine zbijenih traka upotrebom valjak kompaktora,
the dissolution test is performed in 900 mL of dissolution medium containing 0.05 M sodium phosphate at pH 6.8 with 0.05% SDS at 37 °C using USP Apparatus 2 (paddles) at a rotation speed of 75 rpm and the samples are analyzed for apixaban by HPLC at 280 nm. 
test rastvaranja je izveden u 900 mL medija za rastvaranje koji sadrži 0.05 M natrij fosfat pri pH 6.8 sa 0.05% SDS na 37⁰ C korištenjem „USP Apparatus 2“ (lopatica) pri brzini rotacije od 75 o/min i uzorci su analizirani na apiksaban pomoću HPLC na 280 nm.
The mooring buoy (101) of claim 1, wherein the RF communication device (403) is arranged to receive the vessel ID associated with the marine vessel (1004) from a vessel RF communication device located on the marine vessel (1004). 
Plutača za privez (101) prema zahtjevu 1, naznačena time što je RF komunikacijski uređaj (403) postavljen da prima ID plovila koji je povezan s plovilom (1004) iz brodskog RF komunikacijskog uređaja koji se nalazi na plovilu (1004).
The mooring buoy (101) of claim 1 further comprising a communication antenna arranged to communicate with an external booking system (1013) over a communication network. 
Plutača za privez (101) prema zahtjevu 1 naznačena time što nadalje sadrži komunikacijsku antenu postavljenu da komunicira s vanjskim sustavom za rezervaciju (1013) putem komunikacijske mreže.
The mooring buoy (101) of claim 3, wherein the controller is further arranged to transmit a mooring buoy ID to the booking system (1013) and receive booking data from the booking system (1013) via the communication antenna, wherein the booking data comprises at least one booking vessel ID associated with the mooring buoy ID. 
Plutača za privez (101) prema zahtjevu 3, naznačena time što je kontroler nadalje postavljen da prenosi ID plutače za privez u sustav za rezervaciju (1013) i prima podatke o rezervaciji iz sustava za rezervaciju (1013) putem komunikacijske antene, pri čemu podaci o rezervaciji sadrže najmanje jedan rezervacijski ID plovila koji je povezan s ID-om plutače za privez.
The mooring buoy (101) of claim 4, wherein the controller is arranged to activate the RF communication device (403) to receive the vessel ID upon detecting via the movement sensor that the mooring buoy (101) is in a mooring position, and the controller is further arranged to compare the received booking vessel ID with the received vessel ID to determine whether the vessel ID is associated with the mooring buoy (101). 
Plutača za privez (101) prema zahtjevu 4, naznačena time što je kontroler postavljen da aktivira RF komunikacijski uređaj (403) radi prijema ID-a plovila nakon otkrivanja putem senzora kretanja da je plutača za privez (101) u položaju za privez, a kontroler je nadalje postavljen da uspoređuje primljeni rezervacijski ID plovila s primljenim ID-om plovila radi određivanja da li je ID plovila povezan s plutačom za privez (101).
The mooring buoy (101) of claim 3, wherein the controller is arranged to activate the RF communication device to receive the vessel ID upon detecting via the movement sensor that the buoy is in a mooring position, and the controller is further arranged to communicate the vessel ID to the booking system via the cellular antenna. 
Plutača za privez (101) prema zahtjevu 3, naznačena time što je kontroler postavljen da aktivira RF komunikacijski uređaj radi prijema ID plovila nakon otkrivanja putem senzora kretanja da je plutača u položaju za privez, a kontroler je nadalje postavljen da putem mobilne antene komunicira ID plovila prema sustavu za rezervaciju.
The mooring buoy (101) of claim 6, wherein the antenna is further arranged to receive a signal from the booking system to indicate whether or not the vessel ID is associated with the mooring buoy (101). 
Plutača za privez (101) prema zahtjevu 6, naznačena time što je antena nadalje podešena da prima signal iz sustava za rezervaciju da bi se pokazalo da li je ID plovila povezan s plutačom za privez (101).
The mooring buoy (101) of claim 1, wherein the controller is arranged to activate the RF communication device to receive the vessel ID upon detecting via the movement sensor that the mooring buoy (101) is in a mooring position. 
Plutača za privez (101) prema zahtjevu 1, naznačena time što je kontroler prilagođen da aktivira RF komunikacijski uređaj tako da prima ID plovila nakon detektiranja putem senzora kretanja da je plutača za privez (101) u položaju za privez.
The mooring buoy (101) of claim 8, wherein the RF communication device (403) is further arranged to transmit the received vessel ID to a central RF communication device of a mooring buoy booking control system. 
Plutača za privez (101) prema zahtjevu 8, naznačena time što je RF komunikacijski uređaj (403) nadalje prilagođen da prenosi primljeni ID plovila na središnji RF komunikacijski uređaj sustava kontrole rezervacije plutače za privez.
The mooring buoy (101) of claim 9, wherein the RF communication device (403) is further arranged to receive a signal from the central RF communication device of the mooring buoy booking control system to indicate whether or not the marine vessel has been booked for mooring to the mooring buoy (101) via a booking system. 
Plutača za privez (101) prema zahtjevu 9, naznačena time što je RF komunikacijski uređaj (403) nadalje prilagođen da prima signal iz središnjeg RF komunikacijskog uređaja sustava kontrole rezervacije plutače za privez da bi pokazao da li je ili nije plovilo putem rezervacijskog sustava rezervirano za privez na plutaču za privez (101).
The mooring buoy (101) of claim 10 further comprising a visual and/or audible indicator arranged to emit a visual and/or audible signal, wherein the visual and/or audible indicator is arranged to emit the visual and/or audible signal upon the controller determining that the marine vessel moored to the mooring buoy (101) has not been booked for mooring to the mooring buoy (101) via the booking system. 
Plutača za privez (101) prema zahtjevu 10 naznačena time što nadalje sadrži vizualni i/ili zvučni indikator prilagođen da emitira vizualni i/ili zvučni signal, pri čemu je vizualni i/ili zvučni indikator nadalje prilagođen da emitira vizualni i/ili zvučni signal na kontroleru koji utvrđuje da plovilo koje je privezano na plutaču za privez (101) nije preko sustava za rezervaciju rezervirano za privezivanje na plutaču za privez (101).
The mooring buoy (101) of claim 13, wherein the mooring position is obtained by a mooring line of a marine vessel (1004) being attached to the attachment point (209). 
Plutača za privez (101) prema zahtjevu 13, naznačena time što se položaj za privez postiže vezanjem plovila (1004) na mjesto pričvršćenja (209).
The mooring buoy (101) of claim 14 further comprising a GPS device arranged to detect a position of the mooring buoy (101). 
Plutača za privez (101) prema zahtjevu 14 naznačena time što nadalje sadrži GPS uređaj postavljen da detektira položaj plutače za privez (101).
The mooring system of claim 16, wherein the mooring buoy (101) further comprises a visual and/or audible indicator, and, upon a negative determination, the visual and/or audible indicator is arranged to emit a visual and/or audible signal. 
Sustav za privez prema zahtjevu 16, naznačen time što plutača za privez (101) nadalje sadrži vizualni i/ili zvučni indikator, te je pri negativnom određivanju, vizualni i/ili zvučni indikator postavljen da emitira vizualni i/ili zvučni signal.
The mooring system of claim 16, wherein the at least one mooring buoy (101) has a unique ID that is transmitted to the booking system (1013) on a periodic basis to obtain the at least one booked vessel ID from the booking system (1013). 
Sustav za privez prema zahtjevu 16, naznačen time što najmanje jedna plutača za privez (101) ima jedinstveni ID koji se prenosi u sustav za rezervaciju (1013) na periodičnoj osnovi radi dobivanja najmanje jednog rezervacijskog ID-a plovila iz sustava za rezervaciju (1013).
wherein a compound of formula (6): is allowed to react with a compound of formula (6b): thereby providing copanlisib (7): said compound of formula (6): being prepared by the following step A5: 
pri čemu je spoj s formulom (6): ostavljen da reagira sa spojem s formulom (6b): čime se dobiva kopanlisib (7): navedeni spoj s formulom (6): se priprema u sljedećem koraku A5:
wherein a compound of formula (5): is allowed to react with an annelating agent, thereby providing a compound of formula (6); 
pri čemu je spoj s formulom (5): ostavljen da reagira sa sredstvom za žarenje, čime se dobiva spoj s formulom (6);
said compound of formula (5): being prepared by the following step A4: 
navedeni spoj s formulom (5): se priprema u sljedećem koraku A4:
wherein a compound of formula (4): is allowed to react with hydrogen in the presence of a 5% palladium/1% iron catalyst on carbon which is water-wetted, in a solvent, thereby providing a compound of formula (5). 
pri čemu je spoj s formulom (4): ostavljen da reagira s vodikom u prisutnosti 5% paladijevog/1% željezovog katalizatora na ugljiku koji je navlažen vodom, u otapalu, čime se dobiva spoj s formulom (5).
The method according to claim 1, wherein said compound of formula (4): is prepared by the following step A3: 
Postupak prema zahtjevu 1, naznačen time što se navedeni spoj s formulom (4): priprema slijedećim korakom A3:
wherein a compound of formula (3): is allowed to react with ethylenediamine, thereby providing a compound of formula (4). 
pri čemu je spoj s formulom (3): ostavljen da reagira s etilendiaminom, čime se dobiva spoj s formulom (4).
wherein a compound of formula (2): is allowed to react with a compound of formula (2a): thereby providing a compound of formula (3). 
pri čemu je spoj s formulom (2): ostavljen da reagira sa spojem s formulom (2a): čime se dobiva spoj s formulom (3).
wherein a compound of formula (1): 
pri čemu je spoj s formulom (1):
adding a base, thereby providing a compound of formula (2). 
dodavanje baze, čime se dobiva spoj s formulom (2).
wherein a compound of formula (6a): is: 
pri čemu spoj s formulom (6a): se:
allowed to react with a base, with heating, then, 
ostavlja reagirati s bazom, uz grijanje, zatim
after cooling, adding methyl formate, then 
nakon hlađenja se dodaje metil format, zatim
adding guanidine hydrochloride, followed by heating, then, 
se dodaje gvanidin hidroklorid, nakon čega slijedi zagrijavanje, zatim
adding water and an aqueous solution of a base, followed by heating, then, 
se dodaje voda i vodena otopina baze, nakon čega slijedi zagrijavanje, zatim
adding an aqueous solution of a mineral acid, thereby providing a compound of formula (6b): 
dodavanje vodene otopine mineralne kiseline, čime se dobiva spoj s formulom (6b):
The method according to any one of claims 29 to 38, wherein in said step A10, h), said mineral acid is hydrochloric acid. 
Postupak prema bilo kojem od zahtjeva 29 do 38, naznačen time što u navedenom koraku A10, h), navedena mineralna kiselina je klorovodična kiselina.
wherein copanlisib, of formula (7): is allowed to react with hydrogen chloride, thereby providing copanlisib dihydrochloride (8): 
naznačen time što je kopanlisib, s formulom (7): ostavljen da reagira s hidrogen kloridom, čime se dobiva kopanlisib dihidroklorid (8):
A compound selected from: and 
Spoj koji je odabran od: i
A composition comprising imetelstat or imetelstat sodium for use in the treatment of a hematological malignancy in a mammal identified as having a hematological malignancy with the presence of a spliceosome mutation genotype, ringed sideroblasts within bone marrow, or both under conditions wherein said hematological malignancy is treated. 
Pripravak koji sadrži imetelstat ili natrijev imetelstat za uporabu za liječenje hematološke malignosti kod sisavaca koji je identificiran da ima hematološku malignost uz prisutnost genotipa mutacije spliceosoma, prstenastih sideroblasta unutar koštane srži, ili oboje pod uvjetima pri kojim se liječi navedena hematološka malignost.
The composition for the use according to claim 2, wherein said mammal is a mammal identified as having a hematological malignancy with the presence of a spliceosome mutation genotype, ringed sideroblasts within bone marrow, or both. 
Pripravak za uporabu prema zahtjevu 2, naznačen time što navedeni sisavac je sisavac koji je identificiran da ima hematološku malignost uz prisutnost genotipa mutacije spliceosoma, prstenastih sideroblasta unutar koštane srži, ili oboje.
An in vitro method for identifying a mammal having a hematological malignancy with an increased likelihood of responding to treatment with a telomerase inhibitor, wherein said method comprises detecting the presence of a spliceosome mutation genotype, ringed sideroblasts within bone marrow, or both, wherein said presence indicates that said mammal has said hematological malignancy with an increased likelihood of responding to treatment with a telomerase inhibitor. 
In vitro postupak za identificiranje sisavca koji ima hematološku malignost s povećanom vjerojatnošću odgovora na liječenje s inhibitorom telomeraze, naznačen time što navedeni postupak obuhvaća detektiranje prisutnosti genotipa mutacije spliceosoma, prstenastih sideroblasta unutar koštane srži, ili oboje, pri čemu navedena prisutnost ukazuje na to da navedeni sisavac ima navedenu hematološku malignost s povećanom vjerojatnošću odgovora na liječenje s inhibitorom telomeraze.
vinyl aromatic polymers and/or vinyl aromatic copolymers in an amount of at least 50% by weight, calculated with respect to the overall composition, 
vinil aromatske polimere i/ili vinil aromatske kopolimere u količini od barem 50 % po masi, računato u odnosu na ukupni sastav,
a polyolefin or a relative copolymer with an ester in an amount ranging from at least 1% by weight, calculated with respect to the overall composition, 
poliolefin ili relativni kopolimer s esterom u količini u rasponu od barem 1 % po masi, računato u odnosu na ukupni sastav,
an olefinic elastomer grafted with a vinyl aromatic polymer in an amount ranging from 0.01% to 40% by weight, calculated with respect to the sum of (a) + (b), 
olefinski elastomer cijepljen s vinil aromatskim polimerom u količini u rasponu od 0,01 % do 40 % po masi, računato u odnosu na sumu (a) + (b),
The polymeric composition according to any of the claims from 1 to 4, wherein the polyolefin is present in an amount ranging from 10% to 30% by weight. 
Polimerni sastav prema bilo kojem od zahtjeva od 1 do 4, naznačen time što je poliolefin prisutan u količini u rasponu od 10 % do 30 % po masi.
The polymeric composition according to any of the claims from 1 to 8, wherein the molecular weight of the vinyl aromatic polymer grafted on the olefinic elastomer is equal to that of the vinyl aromatic polymer of component (a). 
Polimerni sastav prema bilo kojem od zahtjeva od 1 do 8, naznačen time što je molekularna masa vinil aromatskog polimera cijepljenog na olefinskom elastomeru jednaka onoj vinil aromatskog polimera komponente (a).
A process for preparing, in continuous mass, the expandable composition according to any of the claims from 1 to 11, which comprises the following phases: 
Postupak pripreme, u kontinuiranoj masi, proširivog sastava prema bilo kojem od zahtjeva od 1 do 11, koji sadrži sljedeće faze:
heating said vinyl aromatic polymer and/or vinyl aromatic copolymer to a temperature higher than the relative melting point together with a polyolefin (b) in an amount ranging from at least 1% by weight, and a grafted olefinic elastomer (c) in an amount ranging from 0.01% to 40% by weight, so as to form a polymeric composition in the molten state; 
grijanje navedenog vinil aromatskog polimera i/ili vinil aromatskog kopolimera na temperaturu višu od relativne točke tališta zajedno s poliolefinom (b) u količini u rasponu od barem 1 % po masi, i cijepljenim olefinskim elastomerom (c) u količini u rasponu od 0,01 % do 40 % po masi, kako bi se dobio polimerni sastav u rastaljenom stanju;
ii) if the vinyl aromatic polymer and/or vinyl aromatic copolymer (a) is already in the molten state, adding a polyolefin (b) in an amount ranging from at least 1% by weight, a grafted olefinic elastomer (c) in an amount ranging from 0.01% to 40% by weight and then incorporating an expanding agent so as to form a polymeric composition. 
ii) ukoliko su vinil aromatski polimer i/ili vinil aromatski kopolimer (a) već u rastaljenom stanju, dodavanje poliolefina (b) u količini u rasponu od barem 1 % po masi, cijepljenog olefinskog elastomera (c) u količini u rasponu od 0,01 % do 40 % po masi te zatim uključivanje sredstva za širenje kako bi se dobio polimerni sastav.
A multivalent immunogenic composition comprising the supernatant of a Mycoplasma hyopneumoniae (M.hyo) culture; a porcine circovirus type 2 (PCV2) antigen; and a Lawsonia intracellularis antigen, wherein the supernatant of the M.hyo culture has been separated from insoluble cellular material by centrifugation, filtration or precipitation and is free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin. 
Multivalent imunogeni pripravak, naznačen time što sadrži supernatant kulture bakterije Mycoplasma hyopneumoniae (M.hyo); i antigen iz svinjskog cirkovirusa tip 2 (PCV2), gdje se supernatant kulture M.hyo odvoji od netopljivog staničnog materijala centrifugiranjem, filtriranjem ili taloženjem i ne sadrži ni (i) IgG niti (ii) imunokomplekse koji se sastoje od antigena vezanog na imunoglobulin.
A fumarate salt of compound (I) represented by the following structural formula: 
Fumarat sol spoja (I) je predstavljena slijedećom strukturnom formulom:
wherein the molar ratio between compound (I) and fumaric acid is 1:1. 
pri čemu je molarni odnos između spoja (I) i fumarne kiseline 1:1.
The fumarate salt of claim 3, wherein at least 99% by weight of the fumarate salt is in a single crystalline form. 
Fumarat sol sukladno patentnom zahtjevu 1 ili 2, pri čemu je najmanje 99% težine soli u jednom kristalnom obliku.
The fumarate salt of claim 8, wherein the fumarate salt is single crystalline form B, characterized by differential scanning calorimeter (DSC) peak phase transition temperatures of 58° C. and 162° C. The fumarate salt of claim 10, wherein the fumarate salt is single crystalline form C, characterized by differential scanning calorimeter (DSC) peak phase transition temperatures of 62° C. and 156° C. The fumarate salt of claim 12, wherein the fumarate salt is single crystalline form D, characterized by differential scanning calorimeter (DSC) peak phase transition temperature of 219° C. 
Fumarat sol sukladno bilo kojem od patentnih zahtjeva 1 1-3, i 5, pri čemu je najmanje 90% težine soli fumarata jedan kristalni oblik B, naznačen time što diferencijlna skenirajuća kalorimetrija (DSC) u fazi tranzicije doseže vršne vrijednosti temperatura od 58 °C i 162 °C. Fumarat sol sukladno bilo kojem od patentnih zahtjeva 11-3, i 6, pri čemu je najmanje 90% težine fumarat soli jedan kristalni oblik C, naznačen time što diferencijalna seknirajuća kalorimetrija (DSC) doseže u fazi tranzicije vršne vrijednosti temperatura od 62 °C i 156 °C.
the first volume (V1) is pressurized, and the pressure is maintained in the first volume over a predetermined period of time while the second volume is at the initial pressure and separated from the first volume, 
prvi volumen (V1) je pod tlakom, a tlak se održava u prvom volumenu tijekom unaprijed određenog vremenskog razdoblja dok je drugi volumen na početnom tlaku i odvojen je od prvog volumena,
after successful pressure test the pressure from the first volume (V1) is released, and 
nakon uspješnog tlačnog ispitivanja otpušta se tlak iz prvog volumena (V1), i
A method of assembling and pressure testing a gas valve unit (10) for a gas consumer in a marine vessel, the method comprising: 
Postupak za sastavljanje i tlačno ispitivanje jedinice plinskog ventila (10) za potrošača plina u morskom plovilu, naznačen time što postupak obuhvaća:
pressure testing the space (V2) inside the enclosure (12) and the inlet (18) and the outlet (20), using liquid, 
tlačno ispitivanje prostora (V2) unutar kućišta (12) i ulaza (18) i izlaza (20), korištenjem tekućine,
pressure testing the internal piping (21) using liquid, 
tlačno ispitivanje unutarnjeg cjevovoda (21) korištenjem tekućine,
pressure testing the first volume (V1) while the second volume (V2) is at the initial pressure and separated from the first volume (V1), 
tlačno ispitivanje prvog volumena (V1) dok je drugi volumen (V2) na početnom tlaku i odvojen od prvog volumena (V1),
unblocking the flow communication between the first volume (V1) and the second volume (V2) inside the enclosure with the at least one blocking unit (30). 
deblokiranje protočne komunikacije između prvog volumena (V1) i drugog volumena (V2) unutar kućišta s najmanje jednom jedinicom za blokiranje (30).
The product of any one of claims 4-6, wherein the product has a maximum pit depth of less than 40 microns, or an average pit depth of less than 20 microns. 
Proizvod u skladu s patentnim zahtjevom 8, naznačen time što proizvod ima najveću dubinu udubina manju od 40 mikrometara ili što proizvod ima prosječnu dubinu udubina manju od 20 mikrometara.
An in vitro or ex vivo use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker for screening a drug candidate or vaccine candidate presumed effective in preventing and/or treating a viral infection. 
In vitro ili ex vivo uporaba barem jedne miRNA, navedena barem jedna miRNA je miR-124, kao biomarkera za pregled kandidata za lijek ili kandidata za cjepivo, naročito derivata kinolina, koji se smatra djelotvornim u sprječavanju i/ili liječenju virusne infekcije.
The use according to the preceding claim, wherein a measured level of expression of said miR-124 into an isolated biological sample in presence of said drug candidate or vaccine candidate compared to a control reference value, and wherein a modulation of said measured level relative to said control reference value is indicative of a drug candidate or vaccine candidate effective in preventing and/or treating a viral infection. 
Uporaba prema prethodnim zahtjevima 3 ili 4, naznačena time što se mjeri razina ekspresije navedene miR-124 u izoliranom biološkom uzorku u prisutnosti navedenog kandidata u usporedbi s kontrolnom referentnom vrijednošću, te pri čemu je modulacija navedene izmjerene razine u odnosu na navedenu kontrolnu referentnu vrijednost indikativna za biološki učinak navedenog kandidata, te naročito djelotvornosti navedenog kandidata za lijek ili kandidata za cjepivo za prevenciju i/ili liječenje virusne infekcije
wherein a modulated presence or level of expression of said miRNA relative to said control reference value is indicative of a viral infection. An in vitro or ex vivo method of assessing an activity of an quinoline derivative according to anyone of claims 6 to 8 for preventing and/or treating a viral infection in a patient treated with said quinoline derivative, comprising at least the steps of: a- measuring a presence or an expression level of at least one miRNA, said at least one miRNA being miR-124, in a first biological sample previously obtained from said patient before administering said quinoline derivative and in a second biological sample previously obtained from said patient after administering said quinoline derivative; and 
In vitro ili ex vivo postupak procjenjivanja virusne infekcije kod pacijenta za kojeg se pretpostavlja da je zaražen virusom, naznačen time što sadrži barem korake: a- mjerenje u biološkom uzorku prethodno dobivenom od navedenog pacijenta prisutnosti ili razine ekspresije barem jedne miRNA, navedena barem jedna miRNA je miR-124; i b- uspoređivanje navedene prisutnosti ili razine ekspresije s kontrolnom referentnom vrijednošću, pri čemu je modulirana prisutnost ili razina ekspresije navedene miRNA u odnosu na navedenu kontrolnu referentnu vrijednost indikativna za virusnu infekciju.